Mersana Therapeutics has signed an agreement with EMD Serono, Merck’s biopharmaceutical division, to co-develop next-generation antibody-drug conjugates (ADCs).
Mersana’s Fleximer technology will be used to generate ADCs for multiple undisclosed targets. The two companies will test a variety of ADCs by using Mersana’s platform technologies and several cytotoxic agents as conjugates.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
EMD Serono will provide monoclonal antibodies to Mersana. Mersana will generate the Fleximer-ADCs and conduct drug discovery and preclinical development activities.
EMD Serono will be responsible for clinical development and commercialisation of any products under an exclusive licence from Mersana. Mersana is eligible to receive milestones plus royalties on worldwide net sales of products in addition to an upfront payment.
EMD Serono translational innovation platform oncology head Dr Andree Blaukat said: “We have a long-standing commitment to improving oncology care, and we aim to deliver the best benefit possible to patients.
“Partnering with Mersana allows us to incorporate cutting-edge research and technical excellence to enrich our pipeline.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataADCs are composed of an antibody linked to cytotoxic drugs, where the antibody specifically targets and delivers the cytotoxic drug to cancer cells, which could lead to higher drug levels at the tumour site.
